GitLab Future Growth
Future criteria checks 2/6
GitLab is forecast to grow earnings and revenue by 46.1% and 18.1% per annum respectively. EPS is expected to grow by 51.7% per annum. Return on equity is forecast to be 21.4% in 3 years.
Key information
46.1%
Earnings growth rate
51.7%
EPS growth rate
Software earnings growth | 37.2% |
Revenue growth rate | 18.1% |
Future return on equity | 21.4% |
Analyst coverage | Good |
Last updated | 18 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
1/31/2027 | 1,151 | -140 | 203 | 211 | 11 |
1/31/2026 | 922 | -141 | 119 | 128 | 24 |
1/31/2025 | 738 | -151 | 71 | 77 | 24 |
4/30/2024 | 622 | -426 | 82 | 84 | N/A |
1/31/2024 | 580 | -424 | 33 | 35 | N/A |
10/31/2023 | 539 | -426 | -4 | -2 | N/A |
7/31/2023 | 502 | -190 | 0 | 3 | N/A |
4/30/2023 | 464 | -199 | -65 | -60 | N/A |
1/31/2023 | 424 | -172 | -83 | -77 | N/A |
10/31/2022 | 379 | -179 | -75 | -67 | N/A |
7/31/2022 | 333 | -172 | -82 | -76 | N/A |
4/30/2022 | 290 | -153 | -62 | -56 | N/A |
1/31/2022 | 253 | -155 | -53 | -50 | N/A |
10/31/2021 | 221 | -229 | -55 | -56 | N/A |
7/31/2021 | 196 | -217 | -59 | -60 | N/A |
4/30/2021 | 170 | -198 | -69 | -69 | N/A |
1/31/2021 | 152 | -192 | -75 | -74 | N/A |
1/31/2020 | 81 | -131 | -60 | -60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8K2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 8K2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 8K2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 8K2's revenue (18.1% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 8K2's revenue (18.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8K2's Return on Equity is forecast to be high in 3 years time (21.4%)